Company profile
Sartorius is a leading international partner for the biopharma sector. Our solutions are supporting our customers to develop and produce drugs safely, timely and economically. Founded in 1870, Sartorius currently employs more than 10,600 people in more than 30 countries. Its operational business is subdivided into two divisions: Bioprocess Solutions and Lab Products & Services.

Key Figures
in millions of € unless otherwise specified

<table>
<thead>
<tr>
<th></th>
<th>2020</th>
<th>Δ in %</th>
<th>2019</th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue (Δ in const. fx)</td>
<td>2,335.7</td>
<td>+30.2%</td>
<td>1,827.0</td>
<td>1,566.0</td>
<td>1,404.6</td>
</tr>
<tr>
<td>Order intake (Δ in const. fx)</td>
<td>2,836.3</td>
<td>+49.0%</td>
<td>1,939.5</td>
<td>1,662.5</td>
<td>1,501.4</td>
</tr>
<tr>
<td>Underlying EBITDA(^1)</td>
<td>692.2</td>
<td>+39.6%</td>
<td>495.8</td>
<td>405.0</td>
<td>353.2</td>
</tr>
<tr>
<td>Underlying EBITDA(^1) margin in %</td>
<td>29.6</td>
<td></td>
<td>27.1</td>
<td>25.9</td>
<td>25.1</td>
</tr>
<tr>
<td>Relevant net profit continuing operations(^2)</td>
<td>299.3</td>
<td>+42.9%</td>
<td>209.4</td>
<td>175.6</td>
<td>144.0</td>
</tr>
<tr>
<td>Underlying EPS per ordinary share(^2) in €</td>
<td>4.37</td>
<td>+43.0%</td>
<td>3.06</td>
<td>2.56</td>
<td>2.10</td>
</tr>
<tr>
<td>Underlying EPS per preference share(^2) in €</td>
<td>4.38</td>
<td>+42.9%</td>
<td>3.07</td>
<td>2.57</td>
<td>2.11</td>
</tr>
<tr>
<td>Equity ratio in %</td>
<td>29.9</td>
<td></td>
<td>38.1</td>
<td>38.5</td>
<td>35.1</td>
</tr>
<tr>
<td>Net debt to underlying EBITDA</td>
<td>2.6</td>
<td></td>
<td>2.0</td>
<td>2.4</td>
<td>2.5</td>
</tr>
</tbody>
</table>

Investment Highlights
1. Clear focus on the attractive biopharma sector
2. Long-term growth drivers and significant market entrance barriers
3. Market leading position in key technologies and recognized brand
4. High share of recurring revenue as well as diversified earnings base
5. Proven track record with alliances and acquisitions; strong presence in growth regions

Sales Revenue by Division 2020
Bioprocess Solutions ~74%
Lab Products & Services ~26%

Sales Revenue by Region 2020
Americas 35%
EMEA 40%
Asia | Pacific 25%

EMEA = Europe | Middle East | Africa

2021 Guidance\(^1\)
<table>
<thead>
<tr>
<th></th>
<th>Sales Revenue Growth</th>
<th>EBITDA-Margin(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sartorius Group</td>
<td>~19% - 25%</td>
<td>~30.5%</td>
</tr>
<tr>
<td>Bioprocess Solutions</td>
<td>~22% - 28%</td>
<td>~33.0%</td>
</tr>
<tr>
<td>Lab Products &amp; Services</td>
<td>~10% - 16%</td>
<td>~23.0%</td>
</tr>
<tr>
<td>Capex Ratio</td>
<td>~15%</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) After non-controlling interest, adjusted for extraordinary items as well as non-cash amortization, and based on a normalized financial result and the normalized tax rate
\(^2\) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and the normalized tax rate

Earnings per Share\(^1\) in €

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary shares (SRT)</td>
<td>1.94</td>
<td>2.11</td>
<td>2.57</td>
<td>3.07</td>
<td>4.38</td>
</tr>
<tr>
<td>Preference shares (SRT3)</td>
<td>1.93</td>
<td>2.10</td>
<td>2.56</td>
<td>3.06</td>
<td>4.37</td>
</tr>
</tbody>
</table>

1 Underlying = adjusted for extraordinary items
2 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and the normalized tax rate
Division Strategy

Bioprocess Solutions
- Positioned as a total solution provider for the biopharma industry with a product portfolio covering nearly all steps of the customers' production processes
- Global leading positions in key technology platforms; e.g. process filtration, fluid management, fermentation and cell cultivation
- One of the widest portfolios in the industry; clear focus on single-use technologies such as filters, bags and cell culture media
- Continuous expansion through complementary acquisitions and targeted alliances

Lab Products & Services
- Premium provider of laboratory instruments, consumables and services for sample preparation and bioanalytic
- Leading international positions in laboratory balances, pipettes and lab consumables
- Outstanding brand reputation, strong product range and global services as the basis for further expansion of market share
- Extension of portfolio with complementary laboratory products through acquisitions and alliances

Facts about Preference Shares
Ticker symbol: SRT3
Ticker symbol Bloomberg: SRT3 GY
Ticker symbol Reuters: SATG_pe.DE
WKN | ISIN: 716 563 | DE0007165631

Facts about Ordinary Shares
Ticker symbol: SRT
Ticker symbol Bloomberg: SRT GY
Ticker symbol Reuters: SATG
WKN | ISIN: 716 560 | DE0007165607

Sartorius Shares in Comparison (indexed)
January 1, 2020 to December 31, 2020

Shareholder Structure: Ordinary Shares
December 31, 2020

Administered by an executor ~55%
Bio-Rad Laboratories Inc. ~38%
Free float ~7%

Shareholder Structure: Preference Shares
December 31, 2020

Bio-Rad Laboratories Inc. ~28%
Free float ~72%

The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders' own disclosures. The legal disclosure requirements refer only to ordinary shares and not to non-voting preference shares.

Financial Calendar

March 26, 2021
Annual General Shareholders' Meeting in Göttingen

April 21, 2021
Publication of first-quarter figures for 2021

July 21, 2021
Publication of half-year figures for 2021

October 20, 2021
Publication of third-quarter figures for 2021

Disclaimer

This fact sheet contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbour risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this fact sheet, differences may be apparent as a result of rounding during addition.

Petra Kirchhoff
Head of Corporate Communications
Tel.: +49.551.308.1686
Email: petra.kirchhoff@sartorius.com

Ben Orzelek
Head of Investor Relations
Tel.: +49.551.308.1668
Email: ben.orzelek@sartorius.com